Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
The Ministry of Health, Labor and Welfare (MHLW) plans to submit six bills during the ordinary session of the Diet set to convene on January 23 including legislation to create a so-called Japanese version of the US Centers for Disease…
To read the full story
Related Article
- NCGM President to Take Helm of Japan CDC after April Merger
August 29, 2024
- MHLW Holds 1st Meeting to Consider Structure of Japan CDC
January 26, 2024
- MHLW Preparatory Council Boots Up for Japan-Version of CDC
October 13, 2023
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- Japan Diet Enacts Bill to Create “Japan CDC”
June 1, 2023
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- Lower House Clears Bill to Amend Next-Gen Medical Infrastructure Law
April 14, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- “Pseudonymized Medical Info” to Be Created to Fuel Healthcare Data Use in Filing
January 5, 2023
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
REGULATORY
- MHLW Revises Biological Raw Material Rules, Clarifies Donor Testing Flexibility
April 2, 2026
- Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
April 1, 2026
- MHLW Updates Q&A on Use of Registry Data in Drug Applications
April 1, 2026
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
April 1, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…